Fallopian tube cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The fallopian tubes, which connect the ovaries and the uterus, are where fallopian tube cancer, also known as tubal cancer, develops. It accounts for only 1% to 2% of all gynecologic malignancies, making it incredibly rare. There have been between 1,500 and 2,000 cases of fallopian tube cancer reported worldwide. The first course of treatment for fallopian tube cancers in stages I to IV is surgery. Few female patients with epithelial fallopian tube cancer receive treatment exclusively through surgery. The majority of patients with stage I disease receive adjuvant chemotherapy because of the organ's luminal structure and the potential for cells to burst from the tubes and enter the abdominal cavity.

Description

Fallopian tube cancer, also known as tubal cancer, is a malignancy that affects the fallopian tubes, which connect the ovaries to the uterus. Since it only accounts for 1% to 2% of all gynecologic malignancies, it is incredibly rare. The ovaries or endometrium are two common places from which cancer spreads, or metastasizes, as opposed to the fallopian tubes, which is where it typically starts. Fallopian tube cancer typically strikes females between the ages of 50 and 60, though it can strike anyone at any time.

Fallopian tube cancer (Epidemiology)

Incidences of fallopian tube cancer have been estimated to be between 1,500 and 2,000 worldwide. Between 300 and 400 women in the US are diagnosed with the disease each year. Cancer metastasizes more frequently from other parts of the body, such as the ovaries or endometrium, as opposed to beginning in the fallopian tubes. Fallopian tube cancer most frequently strikes women between the ages of 50 and 60, though it can strike anyone at any time. It tends to occur more frequently in Caucasian women who have had few or no children. Since this cancer is so rare, little is known about its genesis. However, researchers are examining whether genetics are at play. Women who carry the BRCA1 gene, which has been linked to breast and ovarian cancer, are also more likely to develop fallopian tube cancer, per the information that is currently available.

Fallopian tube cancer -Current Market Size & Forecast Trends

The market for fallopian tube cancer is projected to experience significant growth, with estimates indicating a value of around USD 500 million in 2023, expected to reach approximately USD 1.5 billion by 2035, reflecting a compound annual growth rate (CAGR) of 9.06% from 2021 to 2026. This growth is driven by increasing incidence rates, rising awareness, and advancements in treatment options, including targeted therapies like PARP inhibitors. North America is anticipated to dominate the market due to higher incidence rates and substantial healthcare investments, while the Asia-Pacific region is expected to grow rapidly, supported by a large patient population and improved healthcare access. Overall, the fallopian tube cancer market is well-positioned for robust expansion as research and innovation continue to enhance treatment outcomes through 2035.

The first course of treatment for fallopian tube cancers in stages I to IV is surgery. Only a very small percentage of female patients with epithelial fallopian tube cancer receive treatment exclusively through surgery. The majority of patients with stage I disease receive adjuvant chemotherapy because of the organ's luminal structure and the potential for cells to burst from the tubes and enter the abdominal cavity. Staging and tumor debulking are the goals of surgical intervention. The US Food and Drug Administration (FDA) approved bevacizumab (Avastin) for the treatment of people with platinum-resistant, recurrent, epithelial ovarian, fallopian tube, or peritoneal cancers who had only received two previous chemotherapy regimens in November 2014. Olaparib (brand name: Lynparza) may be prescribed to women who have a BRCA1 or BRCA2 gene mutation. Olaparib may also be used as maintenance therapy in women (with or without a BRCA mutation) who have advanced recurrent ovarian cancer that has responded to chemotherapy with a platinum drug like carboplatin or cisplatin. Bevacizumab (Avastin) may be administered along with platinum drugs like carboplatin, taxane drugs like paclitaxel, or other chemotherapy drugs when a cancer diagnosis or recurrence is made. It is injected intravenously every two to three weeks. When used in combination with the chemotherapy drugs paclitaxel, pegylated liposomal doxorubicin, or topotecan for recurrent cancer, bevacizumab typically performs better. Niraparib (Zejula) may be used as a maintenance therapy for women with recurrent fallopian tube cancer who have responded to chemotherapy with a platinum drug such as carboplatin or cisplatin.

Report Highlights

Fallopian tube cancer - Current Market Trends

Fallopian tube cancer - Current & Forecasted Cases across the G8 Countries

Fallopian tube cancer - Market Opportunities and Sales Potential for Agents

Fallopian tube cancer - Patient-based Market Forecast to 2035

Fallopian tube cancer - Untapped Business Opportunities

Fallopian tube cancer - Product Positioning Vis-a-vis Competitors' Products

Fallopian tube cancer - KOLs Insight